MedTrace Logo

A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711

NCT04135820 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-07-09

No results posted yet for this study

Summary

This is an open-label, randomised, single-dose, cross-over phase I study to evaluate the effect of food on the pharmacokinetic profile of BPI-7711 in Chinese healthy male subjects.

Conditions

Interventions

DRUG

BPI-7711

BPI-7711 180 mg

Sponsors & Collaborators

  • Beta Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Yongfang Yuan · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-17
Primary Completion
2020-03-25
Completion
2020-03-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04135820 on ClinicalTrials.gov